Akili Interactive, a digital therapeutics startup from Boston, is hoping to revolutionize how we treat cognitive disorders such as ADHD. The company recently filed their third patent application for the cause, which utilizes AI and a tablet or smartphone to activate the prefrontal cortex and hopefully boost cognitive function. Akili has two iterations of the game in development, one focusing on ADHD and one focusing on Autism spectrum disorder.

In February, the company published results from their most recent clinical trial, in which they saw successful use and adoption by patients, and FDA approval is expected soon. While the company has raised over $140 million through multiple rounds of funding, bringing this alternative treatment to market may be difficult. In March, they announced a partnership with Japanese pharmaceutical company Shinogi, which will support Akili in creating an international digital medicine development and commercialization platform.